Loading company…
ProstaLund AB develops medical technology for male urology, led by its CoreTherm® treatment for benign prostatic hyperplasia.
ProstaLund AB, based in Lund, Sweden, develops medical technologies for male urology, targeting benign prostatic hyperplasia (BPH). Its flagship product, CoreTherm®, uses a patented individualized heat treatment, supported by treatment and anesthetic catheters. The company was acquired by Farstorps Gard Forvaltnings AB in July 2008 and reported revenue of USD 1.73 mn with EBITDA of USD -1.06 mn in fiscal 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in